These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22976374)

  • 1. Brief report: retrospective case series of oxcarbazepine for irritability/agitation symptoms in autism spectrum disorder.
    Douglas JF; Sanders KB; Benneyworth MH; Smith JL; Dejean VM; McGrew SG; Veenstra-Vanderweele J
    J Autism Dev Disord; 2013 May; 43(5):1243-7. PubMed ID: 22976374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary investigation of lithium for mood disorder symptoms in children and adolescents with autism spectrum disorder.
    Siegel M; Beresford CA; Bunker M; Verdi M; Vishnevetsky D; Karlsson C; Teer O; Stedman A; Smith KA
    J Child Adolesc Psychopharmacol; 2014 Sep; 24(7):399-402. PubMed ID: 25093602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study.
    Wake R; Miyaoka T; Inagaki T; Furuya M; Ieda M; Liaury K; Kishi K; Horiguchi J
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):329-36. PubMed ID: 23782127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiepileptic medications in autism spectrum disorder: a systematic review and meta-analysis.
    Hirota T; Veenstra-Vanderweele J; Hollander E; Kishi T
    J Autism Dev Disord; 2014 Apr; 44(4):948-57. PubMed ID: 24077782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management in children and adolescents with pervasive developmental disorder.
    Sung M; Fung DS; Cai Y; Ooi YP
    Aust N Z J Psychiatry; 2010 May; 44(5):410-28. PubMed ID: 20047454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
    Hollander E; Chaplin W; Soorya L; Wasserman S; Novotny S; Rusoff J; Feirsen N; Pepa L; Anagnostou E
    Neuropsychopharmacology; 2010 Mar; 35(4):990-8. PubMed ID: 20010551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxcarbazepine in the treatment of child psychiatric disorders: a retrospective chart review.
    Staller JA; Kunwar A; Simionescu M
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):964-9. PubMed ID: 16379517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study.
    Erickson CA; Veenstra-Vanderweele JM; Melmed RD; McCracken JT; Ginsberg LD; Sikich L; Scahill L; Cherubini M; Zarevics P; Walton-Bowen K; Carpenter RL; Bear MF; Wang PP; King BH
    J Autism Dev Disord; 2014 Apr; 44(4):958-64. PubMed ID: 24272415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.
    Marcus RN; Owen R; Kamen L; Manos G; McQuade RD; Carson WH; Aman MG
    J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1110-1119. PubMed ID: 19797985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorder.
    Fung LK; Libove RA; Phillips J; Haddad F; Hardan AY
    J Autism Dev Disord; 2014 Nov; 44(11):2971-7. PubMed ID: 24849255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
    Posey DJ; Guenin KD; Kohn AE; Swiezy NB; McDougle CJ
    J Child Adolesc Psychopharmacol; 2001; 11(3):267-77. PubMed ID: 11642476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing irritability and aggression in autism spectrum disorders in children and adolescents.
    Robb AS
    Dev Disabil Res Rev; 2010; 16(3):258-64. PubMed ID: 20981764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)].
    Pinheiro D
    Encephale; 2008 Sep; 34(4):409-15. PubMed ID: 18922244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
    Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
    Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy of irritability in pervasive developmental disorders.
    Stigler KA; McDougle CJ
    Child Adolesc Psychiatr Clin N Am; 2008 Oct; 17(4):739-52, vii-viii. PubMed ID: 18775367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case series: use of ziprasidone for maladaptive symptoms in youths with autism.
    McDougle CJ; Kem DL; Posey DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Aug; 41(8):921-7. PubMed ID: 12164181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbamazepine for Irritability and Aggression after Traumatic Brain Injury: A Randomized, Placebo-Controlled Study.
    Hammond FM; Zafonte RD; Tang Q; Jang JH
    J Neurotrauma; 2021 Aug; 38(16):2238-2246. PubMed ID: 33563104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.
    Fung LK; Mahajan R; Nozzolillo A; Bernal P; Krasner A; Jo B; Coury D; Whitaker A; Veenstra-Vanderweele J; Hardan AY
    Pediatrics; 2016 Feb; 137 Suppl 2():S124-35. PubMed ID: 26908468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial.
    Hendouei F; Sanjari Moghaddam H; Mohammadi MR; Taslimi N; Rezaei F; Akhondzadeh S
    J Clin Pharm Ther; 2020 Apr; 45(2):324-334. PubMed ID: 31714621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
    McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
    Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.